Zymeworks Inc. Common Stock - Asset Resilience Ratio

Latest as of September 2025: 47.10%

Zymeworks Inc. Common Stock (ZYME) has an Asset Resilience Ratio of 47.10% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Zymeworks Inc. Common Stock current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$187.10 Million

Cash + Short-term Investments

Total Assets

$397.27 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Zymeworks Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Zymeworks Inc. Common Stock balance sheet assets.

Liquid Assets Composition Over Time

This chart breaks down Zymeworks Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Zymeworks Inc. Common Stock long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$187.10 Million	47.1%
Total Liquid Assets	$187.10 Million	47.10%

Asset Resilience Insights

Very High Liquidity: Zymeworks Inc. Common Stock maintains exceptional liquid asset reserves at 47.10% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Zymeworks Inc. Common Stock Industry Peers by Asset Resilience Ratio

Compare Zymeworks Inc. Common Stock's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
ALK-Abelló A/S CO:ALK-B	Biotechnology	0.98%
Mirum Pharmaceuticals Inc NASDAQ:MIRM	Biotechnology	6.89%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Beijing Konruns Pharmaceutical Co Ltd SHG:603590	Biotechnology	10.55%

Annual Asset Resilience Ratio for Zymeworks Inc. Common Stock (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Zymeworks Inc. Common Stock.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	34.48%	$159.67 Million	$463.09 Million	-2.84pp
2023-12-31	37.32%	$216.77 Million	$580.88 Million	+23.24pp
2022-12-31	14.08%	$91.32 Million	$648.73 Million	+1.04pp
2021-12-31	13.04%	$50.74 Million	$389.13 Million	-21.20pp
2020-12-31	34.24%	$184.32 Million	$538.38 Million	-12.06pp
2019-12-31	46.29%	$170.45 Million	$368.20 Million	-18.35pp
2018-12-31	64.64%	$157.96 Million	$244.36 Million	+25.35pp
2017-12-31	39.29%	$51.85 Million	$131.96 Million	+13.95pp
2016-12-31	25.35%	$23.82 Million	$94.00 Million	+9.62pp
2015-12-31	15.73%	$3.64 Million	$23.15 Million	--

pp = percentage points

About Zymeworks Inc. Common Stock

NASDAQ:ZYME USA Biotechnology

Market Cap

$2.06 Billion

Market Cap Rank

#6586 Global

#2070 in USA

Share Price

$27.48

Change (1 day)

+4.73%

52-Week Range

$16.16 - $31.05

All Time High

$56.81